ResearcherUniversity of PittsburghActive in the last 2 years

Yongkang Gai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6766-5240; OpenAlex author ID A5067881552. Sources: OpenAlex.

Their work

Papers: 4 (first author 1, last author 3)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 9

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 4

Preclinical Development and Comparison of [99mTc]Tc/[177Lu]Lu-Labeled Anti-Trop2 Fc-Fused Nanobodies as Pancreatic Cancer Theranostics. Last author DOI 10.1021/acs.molpharmaceut.5c01039 ↗
Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer. First author DOI 10.1007/s11307-022-01704-6 ↗
Development and Evaluation of a Peptide Heterodimeric Tracer Targeting CXCR4 and Integrin αvβ3 for Pancreatic Cancer Imaging. Last author DOI 10.3390/pharmaceutics14091791 ↗
Synthesis and Preclinical Evaluation of a 68Ga-Radiolabeled Peptide Targeting Very Late Antigen-3 for PET Imaging of Pancreatic Cancer. Last author DOI 10.1021/acs.molpharmaceut.0c00416 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiaoli Lan · 3 shared papers, 2020–2025 · strength 0.49
Dawei Jiang · 1 shared paper, 2025 · strength 0.23
- Paper Preclinical Development and Comparison of [99mTc]Tc/[177Lu]Lu-Labeled Anti-Trop2 Fc-Fused Nanobodies as Pancreatic Canc… DOI 10.1021/acs.molpharmaceut.5c01039 ↗
Feng Yuan · 1 shared paper, 2025 · strength 0.23
- Paper Preclinical Development and Comparison of [99mTc]Tc/[177Lu]Lu-Labeled Anti-Trop2 Fc-Fused Nanobodies as Pancreatic Canc… DOI 10.1021/acs.molpharmaceut.5c01039 ↗
Lingyi Sun · 1 shared paper, 2022 · strength 0.16
- Paper Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer. DOI 10.1007/s11307-022-01704-6 ↗
Rui Kang · 1 shared paper, 2022 · strength 0.16
- Paper Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer. DOI 10.1007/s11307-022-01704-6 ↗
Daolin Tang · 1 shared paper, 2022 · strength 0.16
- Paper Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer. DOI 10.1007/s11307-022-01704-6 ↗
Dexing Zeng · 1 shared paper, 2022 · strength 0.16
- Paper Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer. DOI 10.1007/s11307-022-01704-6 ↗
Yaqun Jiang · 1 shared paper, 2022 · strength 0.15
- Paper Development and Evaluation of a Peptide Heterodimeric Tracer Targeting CXCR4 and Integrin αvβ3 for Pancreatic Cancer Im… DOI 10.3390/pharmaceutics14091791 ↗
Huiling Li · 1 shared paper, 2020 · strength 0.11
- Paper Synthesis and Preclinical Evaluation of a 68Ga-Radiolabeled Peptide Targeting Very Late Antigen-3 for PET Imaging of Pa… DOI 10.1021/acs.molpharmaceut.0c00416 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.